Basit öğe kaydını göster

dc.contributor.authorWolters, E
dc.contributor.authorLane, R
dc.contributor.authorRosa, MM
dc.contributor.authorQuarg, P
dc.contributor.authorTekin, S
dc.contributor.authorEmre, M
dc.contributor.authorAarsland, D
dc.contributor.authorAlbanese, A
dc.contributor.authorByrne, EJ
dc.contributor.authorDeuschl, G
dc.contributor.authorDe Deyn, PP
dc.contributor.authorDurif, F
dc.contributor.authorKulisevsky, J
dc.contributor.authorvan Laar, T
dc.contributor.authorLees, A
dc.contributor.authorPoewe, W
dc.contributor.authorRobillard, A
dc.date.accessioned2021-03-02T21:21:08Z
dc.date.available2021-03-02T21:21:08Z
dc.date.issued2004
dc.identifier.citationEmre M., Aarsland D., Albanese A., Byrne E., Deuschl G., De Deyn P., Durif F., Kulisevsky J., van Laar T., Lees A., et al., "Rivastigmine for dementia associated with Parkinson's disease", NEW ENGLAND JOURNAL OF MEDICINE, cilt.351, sa.24, ss.2509-2518, 2004
dc.identifier.issn0028-4793
dc.identifier.othervv_1032021
dc.identifier.otherav_066d26c9-04fb-4a66-b73f-fb1e1cb5c9ab
dc.identifier.urihttp://hdl.handle.net/20.500.12627/10179
dc.identifier.urihttps://doi.org/10.1056/nejmoa041470
dc.description.abstractBackground: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleRivastigmine for dementia associated with Parkinson's disease
dc.typeMakale
dc.relation.journalNEW ENGLAND JOURNAL OF MEDICINE
dc.contributor.department, ,
dc.identifier.volume351
dc.identifier.issue24
dc.identifier.startpage2509
dc.identifier.endpage2518
dc.contributor.firstauthorID173540


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster